FutureMeds, an independent European Site Management Organization with a growing dedicated research site network, recently launched a new pilot project, FutureMeds go!. The project utilizes decentralization and mobile units to meet patients where they are, boost clinical trial awareness and increase access to new treatments.
FutureMeds go! has been set up in response to the recent and ongoing health emergency caused by the pandemic. Its mission is to reach people who find travel more difficult and costly and give historically overlooked communities access to new treatments.
According to FutureMeds’ initial estimates, a single mobile unit will be able to reach and help over 15,000 patients each year. “The vision of FutureMeds go! is to build a fleet of mobile units that become an actual part of our wider patient and doctor communities.” commented Dr Piotr Rozpondek, MD, PhD, Managing Director of FutureMeds Poland.
Continuing on the trend set by the pandemic, FutureMeds is actively shifting its way of conducting clinical research towards decentralized clinical trials.
Decentralized clinical trial elements such as FutureMeds go! mobile units are an effective approach to overcoming traditional trial challenges such as patient awareness, geographical distance to the sites, time burdens caused by study duration and number of clinical visits. They have multiple benefits for increasing trial efficiency: they can reduce cost, shorten trial timelines and enable faster, more efficient patient recruitment whilst improving patient engagement.
“There are great opportunities for our growing Dedicated Research Site Network at FutureMeds to implement the learnings from the pandemic.” said Radoslaw Janiak, Chief Executive Officer at FutureMeds. “We closely monitored the development cycle of COVID-19 vaccines and examined how their rapid timelines can be replicated in therapeutic areas such as cardiac disease, diabetes and other high-impact conditions. Using the learnings, we are now on a path to accelerate study timelines through thoughtfully used decentralized and hybrid methodologies that can positively impact patients’ access to innovative medicines and the wider industry.”
Replicating and applying the lessons of the COVID-19 vaccine programmes can trigger lasting transformations in the clinical trial industry and bring life-changing therapies to patients faster than ever.
FutureMeds continues to expand its array of patient-focused services to help Sponsors and CROs initiate trials faster, gather accurate data and protect study timelines.
FutureMeds is a fast-growing independent Site Management Organization supporting pharmaceutical companies, Sponsors and CROs and contributing to research to find effective treatments and medications for all patients who need them.
FutureMeds’ Dedicated Research Site teams strive to accelerate study timelines, streamline processes, lower costs and improve data quality to help accelerate patient access to new treatments.
Through acquisitions and a strategic focus on patient experience, the Company has developed qualified patient pools across Europe that enables faster patient enrollment and strong retention and help generate more accurate results.